

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>			Complete if Known		
			Application Number	10/594,826	
			Filing Date	July 17, 2007	
			First Named Inventor	Alan H. Lazarus	
			Art Unit	1644	
			Examiner Name	Ronald B. Schwadron	
Sheet	1	of	1	Attorney Docket Number	1408/6

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	1	Kazatchkine, M.D., and Kaveri, S.V., "Immunomodulation of Autoimmune and Inflammatory Diseases with Intravenous Immune Globulin," New England Journal of Medicine. Vol. 345, No. 10 pgs.:747-755 (2001).	
	2	Rauova et al., "Immunomodulation of autoimmune diseases by high-dose intravenous immunoglobulins," Springer Semin. Immunopathol. Vol. 23 pgs.:447-457 (2001).	
	3	Vassilev et al., "Variable Region-Connected, Dimeric Fraction of Intravenous Immunoglobulin Enriched in Natural Autoantibodies," Journal of Autoimmunity. Vol. 8 pgs.:405-413 (1995).	
	4	Wang et al., "Anti-C5 monoclonal antibody therapy prevents collagen-induced arthritis and ameliorates established disease," PNAS. Vol. 92 pgs.:8955-8959 (1995).	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.